Proteoglycan-19, laminin and collagen type IV production is correlated with the levels of mRNA in F9 cell aggregates differentiating in the presence or absence of cyclic AMP.
F9 embryonal carcinoma cells differentiate to embryoid bodies containing an outer epithelial layer of visceral endoderm cells when cultured as aggregates in medium containing retinoic acid (RA). Another pathway of differentiation to parietal endoderm is followed when dibutyryl cyclic AMP (cAMP) is added to the medium. We have measured the accumulated levels of RNA transcripts from a chondroitin sulfate proteoglycan gene (PG-19), the type IV collagen alpha 1, alpha 2 subunit genes, and laminin B1, B2 subunit genes during these differentiation processes. Laminin B2 gene is uniquely regulated among the extracellular matrix component genes studied. The level of laminin B2 RNA remains almost invariant during RA induction of differentiation but is induced 11-fold by cAMP with RA. In contrast, laminin B1, collagen IV alpha 1, and alpha 2 genes are induced in two stages with six- to sevenfold accumulation of RNA induced by RA and fourfold greater levels by cAMP (19- to 28-fold overall). All of these matrix-encoding genes except proteoglycan are expressed at low levels in unstimulated F9 cells, whereas PG-19 is completely undetectable and is observed only after 2 days of stimulation with RA. Its increased expression with RA and cAMP induction is at least 100-fold during F9 differentiation. Extracellular matrix transcripts are relatively stable and this accounts in part for high accumulated levels during differentiation. We conclude that several kinds of gene regulation occur among the matrix components and other differentiation markers, and this makes the F9 model system useful to study the differential effects of hormone treatments on cellular events leading to differentiation and loss of tumorigenicity.
Grover
A
A
Cancer Research Center, La Jolla Cancer Research Foundation, CA 92037.
Edwards
S A
SA
Bourdon
M
M
Adamson
E D
ED
D003994:Bucladesine / Q000494:pharmacology*; D002454:Cell Differentiation; D011508:Chondroitin Sulfate Proteoglycans / Q000096:biosynthesis* / Q000235:genetics; D003094:Collagen / Q000096:biosynthesis* / Q000235:genetics; D054278:Embryonal Carcinoma Stem Cells; D005109:Extracellular Matrix / Q000032:analysis; D005786:Gene Expression Regulation; D005796:Genes; D006801:Humans; D007797:Laminin / Q000096:biosynthesis* / Q000235:genetics; D014411:Neoplastic Stem Cells; D009693:Nucleic Acid Hybridization; D011509:Proteoglycans / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000032:analysis* / Q000235:genetics; D014158:Transcription, Genetic; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D033921:Vesicular Transport Proteins
D011508:Chondroitin Sulfate Proteoglycans; D007797:Laminin; D011509:Proteoglycans; D012333:RNA, Messenger; D033921:Vesicular Transport Proteins; C075430:serglycin; D014212:Tretinoin; D003994:Bucladesine; D003094:Collagen